SG11202105338VA - Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections - Google Patents
Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infectionsInfo
- Publication number
- SG11202105338VA SG11202105338VA SG11202105338VA SG11202105338VA SG11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroaryldihydropyrimidine
- infections
- derivatives
- methods
- treating hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122258 | 2018-12-20 | ||
| US201962791576P | 2019-01-11 | 2019-01-11 | |
| PCT/CN2019/126739 WO2020125730A1 (en) | 2018-12-20 | 2019-12-19 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105338VA true SG11202105338VA (en) | 2021-07-29 |
Family
ID=71102522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105338VA SG11202105338VA (en) | 2018-12-20 | 2019-12-19 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230165865A1 (pt) |
| EP (1) | EP3898632A4 (pt) |
| JP (1) | JP2022513297A (pt) |
| KR (1) | KR20210106464A (pt) |
| CN (1) | CN113195499A (pt) |
| AU (1) | AU2019410640A1 (pt) |
| BR (1) | BR112021011858A2 (pt) |
| CA (1) | CA3118764A1 (pt) |
| IL (1) | IL284116A (pt) |
| MA (1) | MA54556A (pt) |
| MX (1) | MX2021007602A (pt) |
| SG (1) | SG11202105338VA (pt) |
| TW (1) | TW202035412A (pt) |
| WO (1) | WO2020125730A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11639350B2 (en) | 2017-06-27 | 2023-05-02 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| CN113227090A (zh) * | 2018-12-20 | 2021-08-06 | 詹森药业有限公司 | 杂芳基二氢嘧啶衍生物和治疗乙型肝炎感染的方法 |
| CN111825676B (zh) * | 2019-04-15 | 2023-10-17 | 广东东阳光药业股份有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| WO2020255016A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| CA3140702A1 (en) * | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| TW202246269A (zh) | 2021-01-29 | 2022-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 二氫嘧啶衍生物及其用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之用途 |
| EP4293022A1 (en) * | 2021-02-09 | 2023-12-20 | Shanghai Visonpharma Co., Ltd. | Dihydropyrimidine compound, preparation method therefor and application thereof |
| WO2022257942A1 (en) | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37942B1 (fr) * | 2012-09-10 | 2020-01-31 | Hoffmann La Roche | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b |
| US9266904B2 (en) * | 2013-05-17 | 2016-02-23 | Hoffmann-La Roche Inc. | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| DK3114128T3 (en) * | 2014-03-07 | 2019-03-25 | Hoffmann La Roche | New 6-fused heteroaryld dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| MX2016012573A (es) * | 2014-03-28 | 2018-02-19 | Sunshine Lake Pharma Co Ltd | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. |
| KR20170113658A (ko) * | 2015-03-16 | 2017-10-12 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료 |
| WO2017064156A1 (en) * | 2015-10-16 | 2017-04-20 | F. Hoffmann-La Roche Ag | Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| AR107633A1 (es) * | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
-
2019
- 2019-12-18 TW TW108146369A patent/TW202035412A/zh unknown
- 2019-12-19 AU AU2019410640A patent/AU2019410640A1/en not_active Abandoned
- 2019-12-19 WO PCT/CN2019/126739 patent/WO2020125730A1/en unknown
- 2019-12-19 US US17/415,712 patent/US20230165865A1/en active Pending
- 2019-12-19 JP JP2021534914A patent/JP2022513297A/ja not_active Withdrawn
- 2019-12-19 KR KR1020217020628A patent/KR20210106464A/ko not_active Application Discontinuation
- 2019-12-19 SG SG11202105338VA patent/SG11202105338VA/en unknown
- 2019-12-19 CN CN201980084849.2A patent/CN113195499A/zh active Pending
- 2019-12-19 MA MA054556A patent/MA54556A/fr unknown
- 2019-12-19 BR BR112021011858A patent/BR112021011858A2/pt unknown
- 2019-12-19 CA CA3118764A patent/CA3118764A1/en active Pending
- 2019-12-19 MX MX2021007602A patent/MX2021007602A/es unknown
- 2019-12-19 EP EP19897899.1A patent/EP3898632A4/en not_active Withdrawn
-
2021
- 2021-06-17 IL IL284116A patent/IL284116A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3898632A4 (en) | 2023-02-22 |
| MA54556A (fr) | 2021-10-27 |
| AU2019410640A1 (en) | 2021-05-27 |
| KR20210106464A (ko) | 2021-08-30 |
| CA3118764A1 (en) | 2020-06-25 |
| JP2022513297A (ja) | 2022-02-07 |
| BR112021011858A2 (pt) | 2021-11-30 |
| EP3898632A1 (en) | 2021-10-27 |
| CN113195499A (zh) | 2021-07-30 |
| TW202035412A (zh) | 2020-10-01 |
| IL284116A (en) | 2021-08-31 |
| US20230165865A1 (en) | 2023-06-01 |
| WO2020125730A1 (en) | 2020-06-25 |
| MX2021007602A (es) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3898628A4 (en) | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B VIRUS INFECTIONS | |
| IL284116A (en) | Heteroaryldihydropyrimidine history and methods of treating hepatitis B infections | |
| HK1247147A1 (zh) | 氮雜環辛烷和氮雜環壬烷衍生物以及治療乙型肝炎感染的方法 | |
| EP3472362C0 (en) | PAPD7 AND PAPD5 INHIBITORS TO TREAT HEPATITIS B INFECTION | |
| EP3240787A4 (en) | Derivatives and methods of treating hepatitis b infections | |
| IL246678A0 (en) | History of Azpan and methods of treating jaundice b infections | |
| IL257384A (en) | Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus | |
| HK1251220A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新的四環4-氧代-吡啶-3-甲酸衍生物 | |
| IL281277A (en) | Preparations and methods for treating viral infections | |
| EP3645516A4 (en) | HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS | |
| HK1231402A1 (zh) | 治療 型肝炎和 型肝炎病毒感染的方法 | |
| IL263368A (en) | Prevention and treatment of viral infections | |
| SG11202103567RA (en) | Methods of treatment of inflammatory conditions and associated infections | |
| EP3509596C0 (en) | NORKETOTIFEN FOR THE TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION | |
| EP3634431A4 (en) | THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B | |
| IL290792A (en) | Preparations and methods for treating viral infections | |
| HK1255835A1 (zh) | 用於治療乙型肝炎的治療組合物及方法 | |
| IL271987A (en) | Regimens for the treatment of HIV infections and AIDS | |
| EP3463469C0 (en) | COMBINATION OF LEDIPASVIR AND SOFOSBUVIR FOR USE IN THE TREATMENT OF HEPATITIS B IN HUMAN | |
| EP3675813A4 (en) | METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS | |
| ZA202006569B (en) | Methods of treating fungal infections | |
| HK1254547A1 (zh) | 抗病毒劑和治療病毒感染的方法 | |
| EP3512550A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ENTEROVIRUS INFECTIONS | |
| EP3606516A4 (en) | METHODS OF TREATMENT AND PREVENTION OF INFECTION | |
| EP4077305A4 (en) | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS |